- Chiara Riganti, MD
- Associate professor of biochemistry, Oncological Pharmacology Lab, Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy
Website | E-mail
- Joanna Kopecka, PhD
- Assistant professor of biochemistry, Oncological Pharmacology Lab, Department of Oncology, University of Torino, 10126 Torino, Italy
Website | E-mail
Special Issue Introduction
Despite the recent improvements in our knowledge on glioblastoma genotype and the enlarged spectrum of drugs and drug delivery-technologies developed for glioblastoma, the overall survival of patients with this tumor has not improved in the last years. Chemoresistance can be due to tumor intrinsic factors, mainly related to specific alterations in genotypic, epigenetic and miRNOME profile, or to extrinsic factors, such as the presence of blood-brain barrier and hypoxic niches, that favor the growth of chemoresistant stem cells. Identifying new biomarkers that stratify patients in responders or non-responders to pharmacological therapies, as well as finding innovative strategies improving drug delivery and drug efficacy, are two unmet needs in the current approach to the diagnosis and treatment of this tumor.
This Special Issue will provide an overview of the latest discoveries in terms of biomarkers identification, chemoresistance mechanisms, chemosensitizing strategies for glioblastoma.
KeywordsGlioblastoma; chemoresistance; glioblastoma stem cells; blood-brain barrier; ABC transporters; miRNAs; tyrosine kinase receptors inhibitors; anti-angiogenic drugs; convection-enhanced delivery; nanocarriers
Submission Deadline30 Apr 2020